Formosa Pharmaceuticals is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
News Highlight
- ESG in Action: Formosa Pharmaceuticals Backs the Alliance’s Five Key Actions
- Supporting Local Diversity! Formosa Pharma Sponsors Taipei Bravo PlayOne Women’s Football Team
- Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT™ nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
